STOCK TITAN

Nanoviricides - NNVC STOCK NEWS

Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.

Nanoviricides, Inc. (NNVC) is a clinical-stage biopharmaceutical company pioneering antiviral therapies using proprietary nanomedicine technology. This page serves as the definitive source for verified news and official updates regarding the company's innovative drug development programs.

Investors and researchers will find comprehensive coverage of NNVC's progress including clinical trial developments, regulatory milestones, and strategic partnerships. Our curated collection features press releases on lead candidate NV-387's advancement through clinical studies, updates on broad-spectrum antiviral research, and collaborations advancing nanoviricide platforms.

Key content categories include scientific breakthroughs in host-mimetic nanotechnology, FDA regulatory communications, financial reporting disclosures, and analysis of NNVC's position within the antiviral therapeutics market. All materials are sourced directly from company filings and authorized statements to ensure reliability.

Bookmark this page for streamlined access to NNVC's latest developments in nanoscale antiviral solutions. Check regularly for updates on clinical programs targeting respiratory viruses, herpes-related infections, and other viral pathogens through NNVC's novel therapeutic approach.

Rhea-AI Summary

NanoViricides (NYSE:NNVC) has announced the evaluation of its clinical drug NV-387 for treating Measles virus amid a growing outbreak. The drug, which has completed Phase I trials with no adverse events, has shown effectiveness against multiple viruses that use HSPG for infection, including RSV, COVID-19, Influenza, and MPox.

According to CDC data as of April 11, 2025, there are 712 confirmed Measles cases, with 79 hospitalizations (11%) and 3 deaths. The company is open to enabling NV-387's use under FDA's 'Emergency Expanded Access for an Individual Patient' protocols. NanoViricides plans additional laboratory studies to evaluate NV-387's effectiveness against Measles in cell culture and animal models to support a future IND application.

The company argues that vaccination alone may not be sufficient to control outbreaks, citing a 28% vaccine failure rate among hospitalized cases and the need for 95-97% coverage for herd immunity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.21%
Tags
none
-
Rhea-AI Summary

NanoViricides (NYSE:NNVC) addresses recent stock price decline, emphasizing its immunity to tariffs and government spending cuts. The company's lead drug candidate, NV-387, is a broad-spectrum antiviral showing promise against multiple viruses including measles, RSV, MPox, and influenza.

The company is preparing for a Phase II clinical trial of NV-387 for MPox treatment in Central Africa. NV-387's unique mechanism mimics host-side signatures that viruses target, potentially effective against 90% of human pathogenic viruses. The company also highlights NV-HHV-1, their herpesvirus antiviral candidate, and NV-HIV-1 for HIV/AIDS treatment.

Management believes the recent stock decline alongside market sell-off is misguided, positioning NNVC as a potential hedge against market turmoil due to its strong long-term prospects in antiviral drug development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.21%
Tags
none
-
Rhea-AI Summary

NanoViricides (NNVC) announces its drug candidate NV-387 as a potential treatment for the ongoing measles outbreak, addressing HHS Secretary Kennedy's concern about the lack of approved antivirals. The broad-spectrum antiviral has shown effectiveness against various viruses that use heparan sulfate proteoglycans (HSPG) during cell infection.

The company believes NV-387 could be effective against measles based on two key factors: (1) studies indicating measles virus uses HSPG during cell infection, and (2) its success in treating RSV, which belongs to the same virus family as measles. NanoViricides proposes an investigator-initiated clinical trial to evaluate NV-387 as a measles treatment within FDA regulatory framework.

The announcement comes amid concerns about vaccine effectiveness against new measles variants, with the current Texas outbreak showing that even some vaccinated children are being hospitalized. The outbreak strain (genotype D.8) differs from the vaccine strain (genotype A), highlighting the need for effective treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
none
Rhea-AI Summary

NanoViricides (NYSE:NNVC) has filed its Q4 2024 quarterly report, highlighting its progress with NV-387, a broad-spectrum antiviral drug. The company reported $3.96M in cash and equivalents, with $7.17M in net property and equipment assets. Total current liabilities were $1.18M.

The company is preparing for Phase II clinical trials of NV-387 to treat MPox infection in Central Africa, where clinical trial sites have been identified. NV-387 successfully completed Phase Ia/Ib trials with no adverse events. The drug has shown promising results against various viruses, including Bird Flu H5N1, RSV, Influenza, and MPox.

However, NNVC reported insufficient funding to continue operations through February 14, 2026, for planned objectives. The company raised approximately $4M through an ATM offering and has access to a $3M credit line from its founder.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
-
Rhea-AI Summary

NanoViricides (NYSE:NNVC) announced its readiness to combat bird flu with its broad-spectrum antiviral drug NV-387. The company claims the H5N1 virus cannot escape this drug despite its rapid mutation capability. NV-387 has demonstrated activity against various viruses, including Coronaviruses, Influenza, RSV, and Poxviruses.

Two major H5N1 genotypes are currently circulating: the highly pathogenic D1.1, which caused one death in the US and one critical illness in Canada, and the less pathogenic B3.13, found in dairy cows and workers. While human-to-human transmission hasn't been observed, scientists note that a single point mutation could change this scenario.

In animal studies, NV-387 has shown superior activity compared to existing treatments like Tamiflu, Rapivab, and Xofluza. The company is currently focused on advancing NV-387 into Phase II human clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
none
-
Rhea-AI Summary

NanoViricides (NYSE:NNVC) announced its presentation at the MicroCap Conference 2025 in Atlantic City on January 29, highlighting their lead drug candidate NV-387. The company is advancing towards Phase II clinical trials for MPOX disease treatment in the African Region.

NV-387 has demonstrated broad-spectrum antiviral activity, showing superior results compared to existing treatments in animal models against multiple viruses including Influenza, MPox, RSV, and SARS-CoV-2. The drug mimics a host-side feature used by 90-95% of human pathogenic viruses, making it difficult for viruses to develop resistance.

The company estimates the market size for NV-387 indications to exceed $10 billion. The presentation, scheduled for 11:00 AM at The Borgata Hotel, will be delivered by President and Executive Chairman Anil R. Diwan, PhD, covering updates on the company's drug pipeline and technologies available for licensing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
conferences
Rhea-AI Summary

NanoViricides (NYSE:NNVC) has engaged a Clinical Research Organization to conduct a Phase II clinical trial for its broad-spectrum antiviral drug NV-387, focusing on MPox treatment. The development comes as MPox disease caused a regional pandemic in African countries, leading to WHO declaring a Public Health Emergency in August 2024.

NV-387 has demonstrated strong antiviral activity against orthopoxviruses, matching the effectiveness of tecovirimat in both skin and lung infection models. Unlike tecovirimat, which failed its clinical trial, NV-387's host-mimetic mechanism makes viral escape highly unlikely. The drug has shown promising results in treating RSV and was found superior to existing treatments in influenza models.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
-
Rhea-AI Summary

NanoViricides (NYSE American:NNVC) announced its upcoming presentation at Biotech Showcase™ 2025 in San Francisco on Tuesday, January 14, 2025, at 2:30pm PT. The presentation will be held at the Hilton San Francisco - Union Square.

The company will showcase its Phase II-ready drug NV-387, which has demonstrated broad-spectrum antiviral activity. NV-387 has shown superior effectiveness compared to existing treatments like Tamiflu®, Rapivab®, and Xofluza® in treating Influenza A. The drug has also demonstrated promising results against MPox, Smallpox, RSV, and SARS-CoV-2 infections in animal models.

NV-387's unique mechanism mimics a host-side feature used by 90-95% of human pathogenic viruses, making it difficult for viruses to develop resistance. The overall market size for NV-387 indications is estimated to exceed $10 billion. The company has also developed a platform enabling non-oral drugs to be delivered as active oral drugs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.37%
Tags
conferences
-
Rhea-AI Summary

NanoViricides (NYSE: NNVC) discusses multiple viral threats and their lead drug candidate NV-387. The company highlights concerns about two H5N1 bird flu genotypes: the severe D1.1 form and the less severe B3.13 variant affecting dairy cattle. The first U.S. H5N1 fatality was reported on January 6, 2025, in Louisiana.

NV-387 has shown superior activity compared to existing treatments in animal models against multiple viruses, including Influenza A H3N2, coronavirus, orthopoxvirus, and RSV. The drug's broad-spectrum capability and unique mechanism targeting host-side features make viral escape unlikely, even as viruses evolve.

The company emphasizes that current seasonal outbreaks of COVID-19, RSV, hMPV, and Norovirus, along with emerging H5N1 mutations that can escape vaccines and antibodies, demonstrate the need for broad-spectrum antivirals like NV-387.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.15%
Tags
none
Rhea-AI Summary

NanoViricides (NYSE:NNVC) announces its broad-spectrum antiviral drug candidate NV-387 as a potential solution against H5N1 bird flu pandemic. The company claims the virus is unlikely to develop resistance to NV-387 as it mimics essential host-side features that H5N1 continues to use despite mutations.

In animal studies, NV-387 demonstrated 88% increased survival compared to existing treatments like oseltamivir (25%), peramivir (38%), and baloxivir (38%). The drug has completed Phase I clinical trials with no adverse events and is preparing for Phase II trials for MPox treatment and respiratory virus infections.

The WHO has noted that current H5N1 strains show reduced susceptibility to existing treatments (NAIs and PBIs), highlighting the need for more effective solutions. While the US has stockpiled H5N1 vaccines, their effectiveness against potential pandemic strains remains uncertain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
none
Nanoviricides

NYSE:NNVC

NNVC Rankings

NNVC Stock Data

21.90M
15.07M
3.63%
9.36%
0.9%
Biotechnology
Pharmaceutical Preparations
Link
United States
SHELTON